|
|
|
|
Pramipexole is safe and effective as short-term monotherapy in patients with early PD who are not receiving levodopa.Further study is warranted to determine the long-term impact of pramipexole on the progression of disability in PD and its value in comparison with levodopa therapy and other dopamine agonists. |
|